Edgestream Partners L.P. reduced its position in C.R. Bard, Inc. (NYSE:BCR) by 16.1% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,268 shares of the medical instruments supplier’s stock after selling 244 shares during the quarter. Edgestream Partners L.P.’s holdings in C.R. Bard were worth $401,000 as of its most recent SEC filing.
A number of other institutional investors have also recently bought and sold shares of the stock. CIBC World Markets Inc. raised its position in C.R. Bard by 289.0% in the 2nd quarter. CIBC World Markets Inc. now owns 156,663 shares of the medical instruments supplier’s stock worth $49,523,000 after purchasing an additional 116,394 shares during the period. Engineers Gate Manager LP purchased a new stake in C.R. Bard in the 2nd quarter worth about $1,993,000. WESPAC Advisors LLC raised its position in C.R. Bard by 47.3% in the 2nd quarter. WESPAC Advisors LLC now owns 2,392 shares of the medical instruments supplier’s stock worth $756,000 after purchasing an additional 768 shares during the period. Omni Partners LLP purchased a new stake in C.R. Bard in the 2nd quarter worth about $34,216,000. Finally, Vivaldi Capital Management LLC purchased a new stake in C.R. Bard in the 2nd quarter worth about $5,669,433,000. 79.34% of the stock is currently owned by institutional investors.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by BBNS and is owned by of BBNS. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://baseballnewssource.com/markets/c-r-bard-inc-bcr-shares-sold-by-edgestream-partners-l-p/1604426.html.
A number of analysts recently weighed in on BCR shares. Zacks Investment Research raised shares of C.R. Bard from a “hold” rating to a “buy” rating and set a $360.00 price objective on the stock in a research report on Monday, July 31st. Jefferies Group LLC reaffirmed a “hold” rating on shares of C.R. Bard in a research report on Thursday, August 3rd. BidaskClub lowered shares of C.R. Bard from a “hold” rating to a “sell” rating in a research report on Saturday, August 5th. Finally, BMO Capital Markets reissued a “hold” rating and set a $317.00 price objective on shares of C.R. Bard in a report on Tuesday, July 11th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. C.R. Bard currently has an average rating of “Hold” and an average target price of $285.67.
In other C.R. Bard news, insider John P. Groetelaars sold 23,687 shares of the firm’s stock in a transaction dated Thursday, August 10th. The shares were sold at an average price of $318.73, for a total transaction of $7,549,757.51. Following the completion of the transaction, the insider now directly owns 31,445 shares in the company, valued at approximately $10,022,464.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 0.80% of the stock is owned by company insiders.
C.R. Bard, Inc. (BCR) traded down 0.10% during mid-day trading on Friday, hitting $320.18. 228,662 shares of the stock were exchanged. C.R. Bard, Inc. has a one year low of $203.63 and a one year high of $324.58. The company has a market cap of $23.27 billion, a P/E ratio of 42.03 and a beta of 0.60. The company has a 50-day moving average price of $320.21 and a 200-day moving average price of $296.89.
C.R. Bard (NYSE:BCR) last announced its quarterly earnings data on Thursday, July 27th. The medical instruments supplier reported $2.92 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.84 by $0.08. C.R. Bard had a net margin of 14.99% and a return on equity of 48.70%. The firm had revenue of $979.70 million during the quarter, compared to analysts’ expectations of $976.53 million. During the same quarter last year, the business earned $2.54 earnings per share. The business’s revenue for the quarter was up 5.2% compared to the same quarter last year. Analysts forecast that C.R. Bard, Inc. will post $11.84 earnings per share for the current fiscal year.
C.R. Bard Company Profile
C. R. Bard, Inc (Bard) is engaged in designing, manufacturing, packaging, distribution and sale of medical, surgical, diagnostic and patient care devices. The Company operates through the manufacture and sale of medical devices segment. It sells a range of products to hospitals, individual healthcare professionals, extended care facilities and alternate site facilities on a global basis.
Receive News & Ratings for C.R. Bard Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for C.R. Bard Inc. and related companies with our FREE daily email newsletter.